TrialAIDS (London, England)2013

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Hans-Jürgen Stellbrink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.